SGLT2 Inhibitors and Mechanisms of Cardiovascular Benefit: a State-of-the-art Review

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2018 Aug 23

PMID 30132036

Citations 359

Authors

Subodh Verma

John J V McMurray

Affiliations

Soon will be listed here.

Abstract

Sodium-glucose cotransporter (SGLT)2 inhibitors have been demonstrated to reduce cardiovascular events, particularly heart failure, in cardiovascular outcome trials. Here, we review the proposed mechanistic underpinnings of this benefit. Specifically, we focus on the role of SGLT2 inhibitors in optimising ventricular loading conditions through their effect on diuresis and natriuresis, in addition to reducing afterload and improving vascular structure and function. Further insights into the role of SGLT2 inhibition in myocardial metabolism and substrate utilisation are outlined. Finally, we discuss two emerging themes: how SGLT2 inhibitors may regulate Na/H exchange at the level of the heart and kidney and how they may modulate adipokine production. The mechanistic discussion is placed in the context of completed and ongoing trials of SGLT2 inhibitors in the prevention and treatment of heart failure in individuals with and without diabetes.

Citing Articles

Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV Trial.

Cherney D, Frederich R, Pratley R, Cosentino F, Dagogo-Jack S, Pong A Kidney Dis (Basel). 2025; 11(1):63-74.

PMID: 40028005 PMC: 11870670. DOI: 10.1159/000543162.

Update on the Efficacy and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Chronic Diseases: A Systematic Review and Meta-Analysis.

Liang I, Chang H, Lai Y, Chan C, Sung C, Pu C Medicina (Kaunas). 2025; 61(2).

PMID: 40005319 PMC: 11857657. DOI: 10.3390/medicina61020202.

Myocardial Expression Is Increased in Patients with Impaired Cardiac Contractility and Sleep-Disordered Breathing.

Bayram F, Hegner P, Lauerer A, Schildt S, Wermers D, Baier M Antioxidants (Basel). 2025; 14(2).

PMID: 40002350 PMC: 11851367. DOI: 10.3390/antiox14020163.

Sodium-Glucose Cotransporter-2 Inhibitors and Arrhythmias: A Meta-Analysis of 38 Randomized Controlled Trials.

Jaiswal V, Ang S, Kumar D, Deb N, Jaiswal A, Joshi A JACC Adv. 2025; 4(3):101615.

PMID: 39985887 PMC: 11904486. DOI: 10.1016/j.jacadv.2025.101615.

Impact of sodium‒glucose cotransporter-2 inhibitors in patients with recent versus previous myocardial infarction: a systematic review and meta-analysis.

Scardini P, Shih Katsuyama E, Armani Prata A, Marques Fernandes J, Fukunaga C, Falco Neto W Cardiovasc Diabetol. 2025; 24(1):73.

PMID: 39948563 PMC: 11827181. DOI: 10.1186/s12933-024-02540-4.

References

Lau D, Dhillon B, Yan H, Szmitko P, Verma S . Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol. 2005; 288(5):H2031-41. DOI: 10.1152/ajpheart.01058.2004. View

Fedak P, Verma S, Weisel R, Li R . Cardiac remodeling and failure From molecules to man (Part II). Cardiovasc Pathol. 2005; 14(2):49-60. DOI: 10.1016/j.carpath.2005.01.005. View

Lopaschuk G, Ussher J, Folmes C, Jaswal J, Stanley W . Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010; 90(1):207-58. DOI: 10.1152/physrev.00015.2009. View

Boonman-de Winter L, Rutten F, Cramer M, Landman M, Liem A, Rutten G . High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012; 55(8):2154-62. PMC: 3390708. DOI: 10.1007/s00125-012-2579-0. View

Heise T, Seewaldt-Becker E, Macha S, Hantel S, Pinnetti S, Seman L . Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab. 2013; 15(7):613-21. DOI: 10.1111/dom.12073. View

Lambers Heerspink H, de Zeeuw D, Wie L, Leslie B, List J . Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013; 15(9):853-62. PMC: 3906841. DOI: 10.1111/dom.12127. View

McMurray J, Gerstein H, Holman R, Pfeffer M . Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol. 2014; 2(10):843-51. DOI: 10.1016/S2213-8587(14)70031-2. View

Gallo L, Wright E, Vallon V . Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res. 2015; 12(2):78-89. PMC: 5886707. DOI: 10.1177/1479164114561992. View

Seferovic P, Paulus W . Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J. 2015; 36(27):1718-27, 1727a-1727c. DOI: 10.1093/eurheartj/ehv134. View

10.

Chilton R, Tikkanen I, Cannon C, Crowe S, Woerle H, Broedl U . Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015; 17(12):1180-93. PMC: 5057299. DOI: 10.1111/dom.12572. View

11.

Zinman B, Wanner C, Lachin J, Fitchett D, Bluhmki E, Hantel S . Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22):2117-28. DOI: 10.1056/NEJMoa1504720. View

12.

Fitchett D, Zinman B, Wanner C, Lachin J, Hantel S, Salsali A . Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016; 37(19):1526-34. PMC: 4872285. DOI: 10.1093/eurheartj/ehv728. View

13.

Sattar N, McLaren J, Kristensen S, Preiss D, McMurray J . SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?. Diabetologia. 2016; 59(7):1333-1339. PMC: 4901113. DOI: 10.1007/s00125-016-3956-x. View

14.

Seman L, Macha S, Nehmiz G, Simons G, Ren B, Pinnetti S . Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects. Clin Pharmacol Drug Dev. 2016; 2(2):152-61. DOI: 10.1002/cpdd.16. View

15.

Ferrannini E, Mark M, Mayoux E . CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care. 2016; 39(7):1108-14. DOI: 10.2337/dc16-0330. View

16.

Singh J, Fathi A, Vickneson K, Mordi I, Mohan M, Houston J . Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. Cardiovasc Diabetol. 2016; 15:97. PMC: 4946228. DOI: 10.1186/s12933-016-0419-0. View

17.

Lopaschuk G, Verma S . Empagliflozin's Fuel Hypothesis: Not so Soon. Cell Metab. 2016; 24(2):200-2. DOI: 10.1016/j.cmet.2016.07.018. View

18.

Verma S, Garg A, Yan A, Gupta A, Al-Omran M, Sabongui A . Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?. Diabetes Care. 2016; 39(12):e212-e213. DOI: 10.2337/dc16-1312. View

19.

Baartscheer A, Schumacher C, Wust R, Fiolet J, Stienen G, Coronel R . Empagliflozin decreases myocardial cytoplasmic Na through inhibition of the cardiac Na/H exchanger in rats and rabbits. Diabetologia. 2016; 60(3):568-573. PMC: 6518059. DOI: 10.1007/s00125-016-4134-x. View

20.

Lee T, Chang N, Lin S . Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017; 104:298-310. DOI: 10.1016/j.freeradbiomed.2017.01.035. View